Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 12/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 12/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 8/20 | 0.45 |
| ▸ | PIK3CB | P42338 | 8/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
| ▸ | ATR | Q13535 | 1/20 | 0.35 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.35 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.34 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.34 |
| ▸ | BUB1 | O43683 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3760314 | 0.87 | PIK3CD (0.42) | PIK3CDPIK3CGPIK3CAPIK3CBHTT | |
| SCHEMBL3764807 | 0.85 | PIK3CA (0.43) | PIK3CDPIK3CGPIK3CAPIK3CBHTT | |
| SCHEMBL3760006 | 0.83 | PRKDC (0.39) | PIK3CDPIK3CGPIK3CAPIK3CB | |
| SCHEMBL3765884 | 0.83 | PRKDC (0.41) | PIK3CDPIK3CGPIK3CAPIK3CB | |
| SCHEMBL3757723 | 0.82 | PIK3CA (0.37) | PIK3CDPIK3CGPIK3CAPIK3CBHIF1A | |
| SCHEMBL3761662 | 0.82 | PRKDC (0.45) | PIK3CDPIK3CGPIK3CAPIK3CBHTT | |
| SCHEMBL3770912 | 0.81 | PIK3CA (0.39) | PIK3CDPIK3CGPIK3CAPIK3CBLRRK2 | |
| SCHEMBL3761788 | 0.81 | HTR7 (0.41) | PIK3CDPIK3CGPIK3CAPIK3CB | |
| SCHEMBL3761312 | 0.81 | LRRK2 (0.41) | PIK3CDPIK3CGPIK3CAPIK3CBLRRK2 | |
| SCHEMBL13805581 | 0.80 | PIK3CD (0.37) | PIK3CDPIK3CGPIK3CAPIK3CBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2029570-B1 | FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2014-10-15 | — | — | EP | disclosed |
| US-8324204-B2 | Fused thiophene derivatives as kinase inhibitors | UCB PHARMA SA (BE) | 2012-12-04 | — | — | US | disclosed |
| US-20100305066-A1 | Fused Thiophene Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2010-12-02 | — | — | US | disclosed |
| EP-2029570-A1 | FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma S.A. (BE) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007141504-A1 | FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2007-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305066-A1 | Fused Thiophene Derivatives as Kinase Inhibitors | PIKFYVE, PI4KA, PIK3CA | PIK3CD 9/4885PIK3CG 12/4885PIK3CA 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.